ncov 2019 r

  • 8 min read
  • Mar 19, 2020

Why is Coronavirus 2019 ncov More Dangerous Than SARS ...
Why is Coronavirus 2019 ncov More Dangerous Than SARS …

Revisions were adopted on March 7, 2020, to reflect the following:

Updated March 7, 2020

This is an interim guidance for physicians treating patients with confirmed infection with the weight. acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the disease coronavirus (COVID-19)

This update includes additional information on the latest report include:

CDC will update this interim guidance as more information becomes available.

Among the reports that describe the clinical presentation of patients with confirmed COVID-19, largely limited to patients hospitalized with pneumonia. The incubation period is estimated to 4 days (interquartile range: 2 to 7 days). [] Several studies have estimated a wider range of the incubation period; Data for human infection with other coronaviruses (eg Mers-CoV, SARS-CoV) showed that the incubation period can range from 2-14 days. Commonly reported signs and symptoms of hospitalized patients included fever (77-98%), cough (46% -82%), myalgia or fatigue (11-52%), and shortness of breath (3-31%) in the onset of disease , [-] Among 1,099 hospitalized COVID-19 patients, fever was present in 44% of the time in the hospital, and was developed in 89% during hospitalization. [] Other less commonly reported respiratory symptoms, including sore throat, headache, cough with sputum production and / or hemoptysis. Some patients experience gastrointestinal symptoms such as diarrhea and nausea before developing fever and lower respiratory tract signs and symptoms. Classes fever among patients with COVID-19 is not fully understood; may be prolonged and intermittent. A limited number of reports describe the identification of asymptomatic or subclinical infection on the basis of the detection of SARS-CoV-2 RNA or live virus from throat swab specimens confirmed patient contact. [-]

The risk factors for severe disease that is not yet clear, although older patients and those with chronic medical conditions may be at higher risk for severe disease. Among the more than 44,000 confirmed cases of COVID-19 in China on Feb 11, 2020, the majority occurred among patients aged 30-69 years (77.8%), and approximately 19% are severe or critical illness []. The case-fatality proportion of cases aged ≥60 years are: 60-69 years: 3.6%; 70-79 years: 8%; ≥80 years: 14.8%. Patients who reported no underlying medical condition has a case fatality of 0.9% overall, but deaths higher for patients with comorbidities: 10.5% for those with cardiovascular disease, 7% for diabetes, and 6%, respectively chronic respiratory disease, hypertension, and cancer. Cases of death for patients who develop respiratory failure, septic shock, or multiple organ dysfunction was 49%. []

limited information available about the clinical presentation, clinical and risk factor-19 COVID severe in children. Confirmed COVID-19 patients in China on Feb 11, 2020 only 2.1% were aged <20 years, and no deaths were reported among those <10 years []. Of limited to published reports, the signs and symptoms among children with COVID-19 may be lighter than adults, with the majority of pediatric patients who have fever, cough, congestion, and rhinorrhea [, -], and one report of symptoms, especially gastrointestinal (vomiting and diarrhea) []. Prolonged detection of SARS-CoV RNA have been reported in respiratory specimens (up to 22 days after onset of illness) and stool specimens (at least 30 days after the onset of illness) [-]. severe complications of acute respiratory distress syndrome and septic shock were reported in the 13-month-old with COVID-19 in China [].

The clinical presentation between COVID-19 reported cases vary in severity from asymptomatic infection to mild illness to severe or fatal illness. Some reports indicate potential clinical deterioration during the second week of disease [,] In one report, among patients with a confirmed COVID-19 and pneumonia, more than half of the patients develop dyspnea median of 8 days after the onset of illness (range 5-13 days .: ). [] In another report, the average time from onset of illness to go to the hospital with pneumonia was 9 days. [] Acute respiratory distress syndrome (ARDS), which was developed in 17-29% of patients were hospitalized, and secondary infection developed in 10%. [,] In one report, the median time from symptom onset of ARDS is 8 days. []

Approximately 20-30% of patients hospitalized with pneumonia COVID-19 and has required intensive care for respiratorySupport. [-] Compared with patients who were not treated in the intensive care unit, critically ill patients were older (average age 66 years versus 51 years), and were more likely to have underlying co-morbid conditions (72% versus 37%). [] Among critically ill patients admitted to the intensive care unit, 11-64% receive high flow oxygen therapy and 47-71% received mechanical ventilation; some hospitalized patients have required advanced organ support with endotracheal intubation and mechanical ventilation (4-42%). [-,] A small portion has also been supported by an artificial lung (ECMO, 3-12%). [-,] Other reported complications including cardiac injury, arrhythmia, septic shock, liver dysfunction, acute kidney injury and multi-organ failure. post-mortem biopsy in one patient who died of ARDS reported findings of diffuse alveolar damage lungs. []

A proportion of the overall mortality of 2.3% of cases have been reported among the confirmed cases of COVID-19 in China. [] However, most of these cases were among inpatients and therefore this estimate of fatalities is likely biased upward. Among patients hospitalized with pneumonia, the proportion of deaths have been reported as 4-15%. [-] Among critically ill patients COVID-19 in China, reported the proportion of deaths was 49%. In a report from one of the hospitals, 61.5% of critically ill patients with COVID-19 had died 28 days of admission to the ICU. [,]

Information on specimen collection, handling, and storage is available at :. After initial confirmation COVID-10, additional testing of clinical specimens can help inform clinical management, including discharge planning.

The most common laboratory abnormalities were reported among patients hospitalized with pneumonia on admission included leukopenia (9-25%), leukocytosis (24-30%), lymphopenia (63%), and increased alanine aminotransferase and aspartate aminotransferase levels (37%). [,] Among 1,099 patients COVID 19th, lymphocytopenia was present in 83%; 36% had thrombocytopenia, and 34% have leukopenia. [] Most patients had normal serum levels of procalcitonin on admission. Chest CT images showed bilateral involvement in most patients. Some areas of consolidation and ground glass opacities are typical findings reported to date. [-, -] However, one study that evaluated the time from symptom onset to initial CT scan found that 56% of patients who presented within 2 days had a normal CT. []

The limited data available on the detection of SARS-CoV-2 RNA and infectious virus in clinical specimens. SARS-CoV-2 RNA has been detected from the upper and lower respiratory tract specimens, and the virus has been isolated in cell culture from the upper respiratory tract specimens and bronchoalveolar lavage fluid. In a series of cases of SARS-CoV-2 viral RNA levels within 3 days after the onset of the first symptoms was higher in specimens collected from the nose instead of the throat (as indicated by the threshold value lower cycle in the nose). [] A similar time course and pattern detection of RNA viruses were reported in one patient with no symptoms after being exposed to patients with confirmed COVID-19. []

SARS-CoV-2 RNA has been detected in the blood and stool specimens and SARS-CoV-2 virus has been isolated in cell culture from faeces of patients with pneumonia 15 days after the onset of symptoms. [-]. The duration of the SARS-CoV-2 detection of RNA in the upper and lower respiratory tract and lung specimens is unknown. It is possible that the RNA can be detected for weeks, which has happened in some cases of Mers-CoV or SARS-CoV infection. [-] worthy of SARS-CoV was isolated from respiratory specimens, blood, urine, and feces. Instead, decent Mers-CoV has been isolated only from the respiratory tract specimens. [-].

For more information on infection prevention and control recommendations please see

Patients with mild clinical presentation may initially did not require hospitalization. However, signs and symptoms may worsen clinical development to lower respiratory tract illness during the second week of illness; All patients should be monitored closely. risk factors that are likely to progress to severe disease may include, but are not limited to, older age, and underlying medical conditions such as chronic lung disease, cancer, heart failure, cerebrovascular disease, kidney disease, liver disease, diabetes, immunocompromising condition, and pregnancy.

decision to monitor the patient in the inpatient or outpatient must be made on a case by case basis. This decision will depend not only on the clinical presentation, but also on the patient’s ability to engage in monitoring, home insulation, and the risk of contagion in the patient’s home environment. For more information, see

There is no specific treatment for COVID-19 is currently available. Clinical management includes the rapid implementation of infection control measures recommended and supportive management of complications, including support for advanced organ if indicated.

Corticosteroids should be avoided, because of the potential to prolong viral replication as observed in patients MERS- COV, unless indicated for other reasons. [, -] For example, for chronic obstructive pulmonary disease exacerbations or to septic shock per Surviving Sepsis guidelines for and

For more information, see:. ,, and

There was a time These antiviral drugs no licensed by the Food and drug Administration (FDA) for patients treated with COVID-19. In the United States, the National Institutes of Health (NIH) and collaborators working on the development of candidate vaccines and therapies for COVID-19. Some in-vitro or in-vivo studies showed activity potential therapeutic compounds against coronavirus associated, but no data is available from controlled trials randomized in humans to support recommending any researched therapy for patients with confirmed or suspected COVID-19 today ,

Remdesivir are antiviral medicines studied reported having in-vitro activity against SARS-CoV-2. [] Some patients with COVID-19 has received intravenous remdesivir for use outside the mercy of a clinical trial setting. In China, several clinical trials studied therapy have been implemented, including two clinical trials of remdesivir. A researched therapy for hospitalized COVID-19 patients in the United States have been approved by the Food and Drug Administration; who first studied therapeutic studied are remdesivir. remdesivir other trials COVID-19 patients in the US are available (participants and coronavirus disease). Some patients COVID-19 have received treatment that is not controlled with other antivirus studied. [,,] For more information on the specific clinical trial conducted for the treatment of patients with COVID-19, see, and

With no approved vaccine, community mitigation measures are the main ways to reduce the SARS-CoV – 2 transmission among people in society, and compliance with the measures recommended infection control precautions can reduce the risk of SARS-CoV-2 spread in health facilities. With no approved therapy to demonstrate safety and efficacy in patients with COVID 19th, 19th COVID clinical management of patients including the avoidance of corticosteroids, and supportive care of complications, including advanced organ support.

For recommendations on termination precaution-based transmission-or insulation of homes for patients who have recovered from COVID-19 disease, please see: and

to receive email updates about COVID-19 Please enter your email address:

Transmission of 2019-nCoV Infection from an Asymptomatic Contact ...
Transmission of 2019-nCoV Infection from an Asymptomatic Contact …

Wuhan coronavirus: Symptoms of deadly 2019-nCoV, who is at risk ...
Wuhan coronavirus: Symptoms of deadly 2019-nCoV, who is at risk …

CDC Tests for COVID-19 | CDC
CDC Tests for COVID-19 | CDC

Revisiting the dangers of the coronavirus in the ophthalmology ...
Revisiting the dangers of the coronavirus in the ophthalmology …

Myth busters
Myth busters

Counting is hard, 2019-nCoV edition - Towards Data Science
Counting is hard, 2019-nCoV edition – Towards Data Science

Remdesivir and chloroquine effectively inhibit the recently ...
Remdesivir and chloroquine effectively inhibit the recently …

JCM | Free Full-Text | Estimating the Unreported Number of Novel ...
JCM | Free Full-Text | Estimating the Unreported Number of Novel …

Myth busters
Myth busters

Disease modelers gaze into computers to see future of Covid-19 - STAT
Disease modelers gaze into computers to see future of Covid-19 – STAT

Coronavirus Disease 2019 (COVID-19) | CDC
Coronavirus Disease 2019 (COVID-19) | CDC

Coronavirus: These 2 questions will determine if it becomes a ...
Coronavirus: These 2 questions will determine if it becomes a …

Scientists are racing to model the next moves of a coronavirus ...
Scientists are racing to model the next moves of a coronavirus …

US first coronavirus death is man in King County, Washington ...
US first coronavirus death is man in King County, Washington …

How Does the New Coronavirus Compare with the Flu? - Scientific ...
How Does the New Coronavirus Compare with the Flu? – Scientific …

DNA sleuths read the coronavirus genome, tracing its origins - STAT
DNA sleuths read the coronavirus genome, tracing its origins – STAT

Preliminary estimation of the basic reproduction number of novel ...
Preliminary estimation of the basic reproduction number of novel …

Comparative genetic analysis of the novel coronavirus (2019-nCoV ...
Comparative genetic analysis of the novel coronavirus (2019-nCoV …

Myth busters
Myth busters

2019 Novel Coronavirus (2019-nCoV) Update: Uncoating the Virus
2019 Novel Coronavirus (2019-nCoV) Update: Uncoating the Virus

Viruses | Free Full-Text | Return of the Coronavirus: 2019-nCoV | HTML
Viruses | Free Full-Text | Return of the Coronavirus: 2019-nCoV | HTML

About Coronavirus Disease 2019 (COVID-19) | CDC
About Coronavirus Disease 2019 (COVID-19) | CDC

What do you call the disease caused by the novel coronavirus? Covid-19
What do you call the disease caused by the novel coronavirus? Covid-19

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus ...
Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus …

R-Biopharm is developing a real-time RT-PCR kit for the detection ...
R-Biopharm is developing a real-time RT-PCR kit for the detection …

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Your most pressing questions about the new coronavirus, answered ...
Your most pressing questions about the new coronavirus, answered …

How the China Coronavirus Spread: Full Timeline | Time
How the China Coronavirus Spread: Full Timeline | Time

A Novel Coronavirus from Patients with Pneumonia in China, 2019 | NEJM
A Novel Coronavirus from Patients with Pneumonia in China, 2019 | NEJM

New coronavirus cases reveal the disease
New coronavirus cases reveal the disease’s severity and symptoms …

What do you call the disease caused by the novel coronavirus? Covid-19
What do you call the disease caused by the novel coronavirus? Covid-19

Therapeutic strategies in an outbreak scenario to... | F1000Research
Therapeutic strategies in an outbreak scenario to… | F1000Research

How the China Coronavirus Spread: Full Timeline | Time
How the China Coronavirus Spread: Full Timeline | Time

HAN Archive - 00427 | Health Alert Network (HAN)
HAN Archive – 00427 | Health Alert Network (HAN)

CDC Confirms Person-to-Person Spread of New Coronavirus in the ...
CDC Confirms Person-to-Person Spread of New Coronavirus in the …

Visualizing the progression of the 2019-nCoV outbreak
Visualizing the progression of the 2019-nCoV outbreak

Coronavirus Latest: Feces May Be Hidden Risk of Virus
Coronavirus Latest: Feces May Be Hidden Risk of Virus’s Spread …

How to Conquer Coronavirus: Top 35 Treatments in Development
How to Conquer Coronavirus: Top 35 Treatments in Development

Germany
Germany’s first coronavirus case is human-to-human transmission …

Myth busters
Myth busters

nCoV Reporting and Control
nCoV Reporting and Control

This Is What The COVID-19 Virus Looks Like Under The Microscope
This Is What The COVID-19 Virus Looks Like Under The Microscope

Baricitinib as potential treatment for 2019-nCoV acute respiratory ...
Baricitinib as potential treatment for 2019-nCoV acute respiratory …

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 ...
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 …

Risk Analysis & Coronaviruses: Risk Analysis
Risk Analysis & Coronaviruses: Risk Analysis

eurosurveillance: Vol. 25 Issue 3:
eurosurveillance: Vol. 25 Issue 3:

Transmission dynamics of 2019 novel coronavirus (2019-nCoV) | bioRxiv
Transmission dynamics of 2019 novel coronavirus (2019-nCoV) | bioRxiv

Test for Novel Coronavirus Approved for Wide Deployment | The ...
Test for Novel Coronavirus Approved for Wide Deployment | The …

Coronavirus vs flu: how do they compare? | World Economic Forum
Coronavirus vs flu: how do they compare? | World Economic Forum

Severe acute respiratory syndrome coronavirus 2 - Wikipedia
Severe acute respiratory syndrome coronavirus 2 – Wikipedia

Nowcasting and forecasting the potential domestic and ...
Nowcasting and forecasting the potential domestic and …

qMAXSen™ One-Step RT-qPCR Kit for Coronavirus Detection (Strain ...
qMAXSen™ One-Step RT-qPCR Kit for Coronavirus Detection (Strain …

WHO holds off on nCoV emergency declaration as cases soar | CIDRAP
WHO holds off on nCoV emergency declaration as cases soar | CIDRAP

Protein structure and sequence re-analysis of 2019-nCoV genome ...
Protein structure and sequence re-analysis of 2019-nCoV genome …

Tinggalkan Balasan

Alamat email Anda tidak akan dipublikasikan. Ruas yang wajib ditandai *